Abstract
Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.
| Original language | English |
|---|---|
| Pages (from-to) | 293-298 |
| Number of pages | 6 |
| Journal | Korean Journal of Laboratory Medicine |
| Volume | 29 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2009 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry
- Biochemistry, medical
Cite this
}
Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea. / Roh, Kyoung Ho; Kim, Sinyoung; Kim, Chang Ki; Yum, Jong Hwa; Kim, Myung Sook; Yong, Dongeun; Lee, Kyungwon; Kim, June Myung; Chong, Yunsop.
In: Korean Journal of Laboratory Medicine, Vol. 29, No. 4, 01.12.2009, p. 293-298.Research output: Contribution to journal › Article
TY - JOUR
T1 - Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea
AU - Roh, Kyoung Ho
AU - Kim, Sinyoung
AU - Kim, Chang Ki
AU - Yum, Jong Hwa
AU - Kim, Myung Sook
AU - Yong, Dongeun
AU - Lee, Kyungwon
AU - Kim, June Myung
AU - Chong, Yunsop
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.
AB - Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.
UR - http://www.scopus.com/inward/record.url?scp=73349102191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73349102191&partnerID=8YFLogxK
U2 - 10.3343/kjlm.2009.29.4.293
DO - 10.3343/kjlm.2009.29.4.293
M3 - Article
C2 - 19726890
AN - SCOPUS:73349102191
VL - 29
SP - 293
EP - 298
JO - Annals of Laboratory Medicine
JF - Annals of Laboratory Medicine
SN - 2234-3806
IS - 4
ER -